Clinical Trial Update: Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports efficacy and safety results for JM-010 in Parkinson's disease patients with levodopa-induced dyskinesia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Levodopa-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• JM-010

Snippet

Sponsor: Bukwang Pharmaceutical | Conditions: Parkinson's Disease, Levodopa Induced Dyskinesia (LID) | Phase 2 | Status: COMPLETED